GlaxoSmithKline/Adolor Halt Entereg Bowel Dysfunction Program Due To Cardiovascular Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-line, 12-month Phase III safety data underscore CV concerns and raise new adverse event questions.
You may also be interested in...
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus
Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.